ClinicalTrials.gg

Program

Allocetra

Its studies are mostly in Osteoarthritis, Knee · Osteoarthritis · Arthritis, Psoriatic, led by Enlivex Therapeutics.

Furthest: phase 2, since Jan 22, 20243 company-led studies, 1 open or runningNext primary completion: Feb 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Enlivex Therapeutics31 open or runningphase 2since Jan 22, 2024Jan 22, 2024Feb 2027phase 2 · NCT07580716

Also a collaborator on its studies: nordic-bioscience-clinical-development.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 22, 2024First study: phase 2 study in Osteoarthritis, KneeFirst studyNCT06233474 · 134 enrolled · Denmark, Israel, Moldova
  2. Jul 7, 2024Phase 1 study in Arthritis, PsoriaticNCT06522035 · 5 enrolled · Israel
  3. Apr 23, 2026Phase 2 study in OsteoarthritisNCT07580716 · 182 planned · United States, Denmark, Poland

Ahead

  1. Feb 2027Primary completion: phase 2 study in OsteoarthritisNCT07580716

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07580716Osteoarthritis · United States, Denmark, Poland2RecruitingFeb 2027182
NCT06522035Arthritis, Psoriatic · Israel1TerminatedOct 20, 20255
NCT06233474Osteoarthritis, Knee · Denmark, Israel, Moldova2CompletedMar 15, 2026134

How it is read

Names in the registry

  • “Allocetra”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.